Recipharm wins 3-year Parkinson’s drug contract
LobSor Pharmaceuticals, based in Uppsala, is developing Lecigon, a treatment for advanced Parkinson’s disease currently at clinical stage.
Swedish contract development and manufacturing organisation (CDMO) Recipharm will manufacture the drug in its first three years on the market, and will help pay for development costs before then “against a mark-up on manufacturing prices, up to a certain volume, when Lecigon is produced for commercial sales.”
The three-year agreement follows a previous deal whereby Recipharm manufactured the Parkinson’s candidate for a recent clinical trial.
‘Costly and cumbersome’
Carl-Johan Spak, executive vice president of development and technology, Recipharm, said “We are extremely pleased to have developed our collaborative partnership with LobSor Pharmaceuticals and to have signed an agreement for the future commercial manufacturing of Lecigon, especially as this is a new, innovative drug, which we believe provides a clear benefit to patients with advanced Parkinson’s disease.”
Roger Bolsöy, MD of LobSor Pharmaceuticals added “It is well known that pharmaceutical development is costly and can be cumbersome for a small company.
“Recipharm is one of our most important strategic partners for the development of our first pharmaceutical product, with whom we have been able to find creative collaboration models to secure the initiation of the Lecigon project.
“I am impressed that such a large organization as Recipharm has been able to show such entrepreneurial spirit and flexibility to facilitate the development of a company from the early stages through to commercialization.”
